Drugmakers Take Reglan Preemption Appeal To Pa. High Court

Law360, Philadelphia (November 6, 2013, 5:19 PM EST) -- Several drugmakers asked the Pennsylvania Supreme Court last week to hear an appeal of a decision allowing thousands of product liability claims over alleged injuries tied to generic versions of the digestive drug Reglan to proceed because they weren’t preempted by federal law.

Led by Teva Pharmaceuticals USA Inc. and Pliva Inc., the drugmakers argued that a split decision by a three-judge Superior Court panel in July ignored precedents set by two U.S. Supreme Court rulings which found that failure-to-warn claims brought under state law were...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.